Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (5): 793-801. doi: 10.19723/j.issn.1671-167X.2023.05.004
Previous Articles Next Articles
Huan-rui LIU1,Xiang PENG1,2,Sen-lin LI1,Xin GOU1,*()
CLC Number:
1 |
AneoniS , FerlayJ , SoerjomatarmI ,et al.Bladder cancer incidence and mortality: A global overview and recent trends[J].Eur Urol,2017,71(1):96-108.
doi: 10.1016/j.eururo.2016.06.010 |
2 |
NielsenME , SmithAB , MererAM ,et al.Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the Uni-ted States: 1988 to 2006[J].Cancer,2014,120(1):86-95.
doi: 10.1002/cncr.28397 |
3 |
CrispenPL , KusmartsevS .Mechanisms of immune evasion in bladder cancer[J].Cancer Immunol Immunother,2020,69(1):3-14.
doi: 10.1007/s00262-019-02443-4 |
4 |
Goossens-LaanCA , LeliveldAM , VerhoevenRH ,et al.Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer[J].Int J Cancer,2014,135(4):905-912.
doi: 10.1002/ijc.28716 |
5 | Redondo-GonzalezE , de CastroLN , Moreno-SierraJ ,et al.Bladder carcinoma data with clinical risk factors and molecular mar-kers: A cluster analysis[J].Biomed Res Int,2015,2015,168682. |
6 |
MoasserMM .The oncogene HER2 : Its signaling and transforming functions and its role in human cancer pathogenesis[J].Oncogene,2007,26(45):6469-6487.
doi: 10.1038/sj.onc.1210477 |
7 |
BegnamiMD , FukudaE , FregnaniJH ,et al.Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome[J].J Clin Oncol,2011,29(22):3030-3036.
doi: 10.1200/JCO.2010.33.6313 |
8 |
BangYJ , van CutsemE , FeyereislovaA ,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial[J].Lancet,2010,376(9742):687-697.
doi: 10.1016/S0140-6736(10)61121-X |
9 |
WolffAC , HammondME , HicksDG ,et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Patho-logists clinical practice guideline update[J].J Clin Oncol,2013,31(31):3997-4013.
doi: 10.1200/JCO.2013.50.9984 |
10 |
IyerG , Al-AhmadieH , SchultzN ,et al.Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer[J].J Clin Oncol,2013,31(25):3133-3140.
doi: 10.1200/JCO.2012.46.5740 |
11 |
BaiX , HeW , YinH ,et al.Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single-center experience[J].Exp Ther Med,2022,24(5):704.
doi: 10.3892/etm.2022.11640 |
12 |
LoiS , SirtaineN , PietteF ,et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase Ⅲ randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98[J].J Clin Oncol,2013,31(7):860-867.
doi: 10.1200/JCO.2011.41.0902 |
13 |
StantonSE , AdamsS , DisisML .Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review[J].JAMA Oncol,2016,2(10):1354-1360.
doi: 10.1001/jamaoncol.2016.1061 |
14 |
JiaY , KodumudiKN , RamamoorthiG ,et al.Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway[J].Mol Ther,2021,29(4):1541-1556.
doi: 10.1016/j.ymthe.2020.12.037 |
15 |
WülfingC , MachielsJP , RichelDJ ,et al.A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma[J].Cancer,2009,115(13):2881-2890.
doi: 10.1002/cncr.24337 |
16 |
ShengX , YanX , WangL ,et al.Open-label, multicenter, phase Ⅱ study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma[J].Clin Cancer Res,2021,27(1):43-51.
doi: 10.1158/1078-0432.CCR-20-2488 |
17 | ShengX , ZhouAP , YaoX ,et al.A phase Ⅱ study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma[J].J Clin Oncol,2019,37(Suppl 15):4509. |
18 |
RushJS , PetersonJL , CeresaBP .Betacellulin (BTC) biases the EGFR to dimerize with ErbB3[J].Mol Pharmacol,2018,94(6):1382-1390.
doi: 10.1124/mol.118.113399 |
19 |
ShenT , YangT , YaoM ,et al.BTC as a novel biomarker contri-buting to EMT via the PI3K-AKT pathway in OSCC[J].Front Genet,2022,13,875617.
doi: 10.3389/fgene.2022.875617 |
20 |
DahlhoffM , WolfE , SchneiderMR .The ABC of BTC: Structural properties and biological roles of betacellulin[J].Semin Cell Dev Biol,2014,28,42-48.
doi: 10.1016/j.semcdb.2014.01.002 |
21 |
OlsenDA , KjaerIM , BrandslundI .Development of a three-plex single molecule immunoassay enabling measurement of the EGFR ligands amphiregulin, betacellulin and transforming growth factor alpha simultaneously in human serum samples[J].J Immunol Methods,2018,459,63-69.
doi: 10.1016/j.jim.2018.05.002 |
22 | LeeYS , SongGJ , JunHS .Betacellulin-induced alpha-cell proli-feration is mediated by ErbB3 and ErbB4, and may contribute to beta-cell regeneration[J].Front Cell Dev Biol,2020,8,605110. |
23 | OlsenDA , BechmannT , ϕstergaardB ,et al.Increased concentrations of growth factors and activation of the EGFR system in breast cancer[J].Clin Chem Lab Med,2012,50(10):1809-1818. |
24 |
PearlLH .Hsp90 and Cdc37: A chaperone cancer conspiracy[J].Curr Opin Genet Dev,2005,15(1):55-61.
doi: 10.1016/j.gde.2004.12.011 |
25 |
SerwetnykMA , BlaggBSJ .The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition[J].Acta Pharm Sin B,2021,11(6):1446-1468.
doi: 10.1016/j.apsb.2020.11.015 |
26 |
GrayPJ , Jr. , PrinceT , ChengJ ,et al.Targeting the oncogene and kinome chaperone CDC37[J].Nat Rev Cancer,2008,8(7):491-495.
doi: 10.1038/nrc2420 |
27 |
GhatakS , MisraS , TooleBP .Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells[J].J Biol Chem,2005,280(10):8875-8883.
doi: 10.1074/jbc.M410882200 |
28 |
HuangW , YeM , ZhangLR ,et al.FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation[J].Mol Cancer,2014,13,150.
doi: 10.1186/1476-4598-13-150 |
29 |
Esparís-OgandoA , MonteroJC , ArribasJ ,et al.Targeting the EGF/HER ligand-receptor system in cancer[J].Curr Pharm Des,2016,22(39):5887-5898.
doi: 10.2174/1381612822666160715132233 |
30 | WangZ .ErbB receptors and cancer[J].Methods Mol Biol,2017,1652,3-35. |
31 | GarousiS , Jahanbakhsh-GodehkahrizS , EsfahaniK ,et al.Meta-analysis of EGF-stimulated normal and cancer cell lines to discover EGF-associated oncogenic signaling pathways and prognostic biomarkers[J].Iran J Biotechnol,2022,20(3):e3245. |
32 | LaczmanskaI , SasiadekMM .Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer[J].Acta Biochim Pol,2011,58(4):467-470. |
33 |
MenigattiM , CattaneoE , Sabates-BellverJ ,et al.The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis[J].Mol Cancer,2009,8,124.
doi: 10.1186/1476-4598-8-124 |
34 |
WangY , CaoJ , LiuW ,et al.Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin[J].J Biol Chem,2019,294(48):18306-18323.
doi: 10.1074/jbc.RA119.010348 |
35 |
SuPH , LinYW , HuangRL ,et al.Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer[J].Oncogene,2013,32(1):15-26.
doi: 10.1038/onc.2012.29 |
36 |
MunkleyJ , LaffertyNP , KalnaG ,et al.Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells[J].BMC Cancer,2015,15,9.
doi: 10.1186/s12885-015-1012-8 |
37 |
ChengWL , FengPH , LeeKY ,et al.The role of EREG/EGFR pathway in tumor progression[J].Int J Mol Sci,2021,22(23):12828.
doi: 10.3390/ijms222312828 |
38 |
ZhangL , NanF , YangL ,et al.Differentially expressed EREG and SPP1 are independent prognostic markers in cervical squamous cell carcinoma[J].J Obstet Gynaecol Res,2022,48(7):1848-1858.
doi: 10.1111/jog.15265 |
39 |
LiuS , WangY , HanY ,et al.EREG-driven oncogenesis of head and neck squamous cell carcinoma exhibits higher sensitivity to erlotinib therapy[J].Theranostics,2020,10(23):10589-10605.
doi: 10.7150/thno.47176 |
40 |
XiaQ , ZhouY , YongH ,et al.Elevated epiregulin expression predicts poor prognosis in gastric cancer[J].Pathol Res Pract,2019,215(5):873-879.
doi: 10.1016/j.prp.2019.01.030 |
[1] | Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811. |
[2] | Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707. |
[3] | Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529. |
[4] | Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253. |
[5] | Yu-mei LAI,Zhong-wu LI,Huan LI,Yan WU,Yun-fei SHI,Li-xin ZHOU,Yu-tong LOU,Chuan-liang CUI. Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 262-269. |
[6] | Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282. |
[7] | Qian SU,Xin PENG,Chuan-xiang ZHOU,Guang-yan YU. Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 13-21. |
[8] | Quan ZHANG,Hai-feng SONG,Bing-lei MA,Zhe-nan ZHANG,Chao-hui ZHOU,Ao-lin LI,Jun LIU,Lei LIANG,Shi-yu ZHU,Qian ZHANG. Pre-operative prognostic nutritional index as a predictive factor for prognosis in non-metastatic renal cell carcinoma treated with surgery [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 149-155. |
[9] | Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218. |
[10] | Le-qing CAO,Jing-rui ZHOU,Yu-hong CHEN,Huan CHEN,Wei HAN,Yao CHEN,Yuan-yuan ZHANG,Chen-hua YAN,Yi-fei CHENG,Xiao-dong MO,Hai-xia FU,Ting-ting HAN,Meng LV,Jun KONG,Yu-qian SUN,Yu WANG,Lan-ping XU,Xiao-hui ZHANG,Xiao-jun HUANG. Relationship between treatment and prognosis in patients with late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 1013-1020. |
[11] | Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620. |
[12] | Fei WANG,Cai-peng QIN,Yi-qing DU,Shi-jun LIU,Qing LI,Tao XU. Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 669-673. |
[13] | Min QIU,Yan-yan LIAN,Min LU,Bin-shuai WANG,Xiao-jun TIAN,Jian LU,Cheng LIU,Shu-dong ZHANG,Min JIANG,Lu-lin MA. Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 680-685. |
[14] | Yu-han DENG,Yong JIANG,Zi-yao WANG,Shuang LIU,Yu-xin WANG,Bao-hua LIU. Long short-term memory and Logistic regression for mortality risk prediction of intensive care unit patients with stroke [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 458-467. |
[15] | LAN Lin,HE Yang,AN Jin-gang,ZHANG Yi. Relationship between prognosis and different surgical treatments of zygomatic defects: A retrospective study [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 356-362. |
|